Top Markets
Coin of the day
Merck & Co., Inc. Merck & Co., Inc.

Merck & Co., Inc.

MRK
주식 순위 #40
Merck & Co., Inc. is a global healthcare leader with operations spanning two... Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
주가
$152.37
시가총액
$376.33B
변동 (1일)
12.46%
변동 (1년)
79.41%
국가
US
거래 Merck & Co., Inc. (MRK)

카테고리

Merck & Co., Inc. (MRK)의 P/E 비율
August 2026 기준 P/E 비율 TTM: 107.81
Merck & Co., Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 107.81입니다. 2024년 말 기준 P/E 비율은 14.72였습니다.
Merck & Co., Inc.의 P/E 비율 기록 (2000 ~ 2026)
매년 말 P/E 비율
연도 P/E 비율 변화
2026 (TTM) 107.81 645.57%
2025 14.46 -1.74%
2024 14.72 -98.11%
2023 778.71 3,924.61%
2022 19.35 30.21%
2021 14.86 -46.79%
2020 27.92 23.57%
2019 22.60 -25.59%
2018 30.37 -49.75%
2017 60.43 53.54%
2016 39.36 24.80%
2015 31.54 144.60%
2014 12.89 -59.36%
2013 31.72 65.59%
2012 19.16 9.91%
2011 17.43 -85.89%
2010 123.55 2,069.42%
2009 5.70 -28.19%
2008 7.93 -78.40%
2007 36.72 79.85%
2006 20.42 41.90%
2005 14.39 23.34%
2004 11.67 -19.12%
2003 14.42 -15.38%
2002 17.04 -3.27%
2001 17.62 -41.63%
2000 30.19 0.00%
유사 기업 또는 경쟁사의 P/E 비율
회사 P/E 비율 P/E 비율 차이 국가
39.54 -63.33%
US
30.10 -72.08%
US
70.28 -34.81%
US
22.25 -79.36%
CH
22.23 -79.38%
CH
P/E 비율 읽는 방법

P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.

P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.

양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.